On 1 April PrEP will be available on the PBS
On 21 March 2018, the Federal Minister for Health announced that PrEP will be subsidised by the Australian Government through the Pharmaceutical Benefits Scheme (PBS) from 1 April 2018. For more information about what this means please see the AFAO PrEP Factsheet.
HIV Pre-Exposure Prophylaxis (PrEP) is the regular use of HIV medications by HIV-negative people to prevent HIV acquisition.
People at high risk of HIV are eligible for PrEP. In Australia, some sexually active gay and bisexual men, transgender people and heterosexual people with an HIV positive partner who does not have an undetectable viral load are population groups that are at high risk.
Research shows that the medication used for PrEP is highly effective at preventing HIV transmission among these population groups.
PrEP has the potential to significantly impact Australia’s response to the HIV epidemic. It is an important new option in the suite of HIV prevention strategies and, alongside treatment as prevention, will support Australia to meet its target of ending HIV transmission.